Valuation
- Market cap
- 853,583,000
- Revenue TTM
- $376,130,000
- Net income TTM
- $2,850,000
- P/E (trailing)
- 39.34
- P/E (forward)
- 37.58
- Profit margin
- 0.76%
- Debt to equity
- 0.02
Trading
- Volume
- 5,900
- Avg volume
- 23,030
- Day's range
- $12.30 – $12.48
- Shares out
- 70,778,000
- Stochastic %K
- 30%
- Beta
- -0.05
- Analysts
- Strong Buy
- Price target
- $39.00
Company profile
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniol...
Show more
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3Kd inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 31 71 524 7400
- Website
- https://www.pharming.com
- Address
- Darwinweg 24, Leiden, Netherlands
Latest news
No headlines yet.